Equity Overview
Price & Market Data
Price: $0.532
Daily Change: +$0.0123 / 2.31%
Range: $0.50 - $0.575
Market Cap: $2,550,618
Volume: 1,111,331
Performance Metrics
1 Week: 21.58%
1 Month: 34.24%
3 Months: 11.48%
6 Months: 7.90%
1 Year: -78.85%
YTD: -13.95%
Company Details
Employees: 2
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Entero Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. It develops Adrulipase, an oral, non-systemic, and biologic capsule that is in Phase 2 clinical trials for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis (CF) and chronic pancreatitis (CP), as well as a recombinant lipase enzyme that enables the digestion of fats and other nutrients in CF and CP patients with EPI. The company was formerly known as First Wave BioPharma, Inc. and changed its name to Entero Therapeutics, Inc. in May 2024. Entero Therapeutics, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida.